Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteins

Purpose Testicular Germ Cell Tumors (TGCTs) are the most frequent solid malignancies in young adult men.

Regardless of differences in their cell of origin, all TGCTs are considered highly curable malignancies.

However, approximately 3–5% of all TGCTs do not respond to platinum-based chemotherapies.

The purpose of our paper is to investigate whether immunohistochemical expression of MLH1 and REV-7 can be used as predictive tissue markers for TGCTs.

Material and Methods The main demographic and clinicopathological characteristics of 64 male patients with TGCTs who underwent orchiectomy from 2007 to 2022 were retrospectively obtained from two large Oncology Clinics in Greece.

Both patients with chemosensitive and chemoresistant disease were included.

Immunohistochemical staining for MLH1 and REV-7 proteins was applied in specimens of these patients.

Results 31 seminomas and 33 non-seminomas were included.

48 patients had chemosensitive disease, while 16 had chemoresistant disease.

53 specimens showed preserved MLH1 expression, while 11 specimens had lost MLH1 expression.

Expression of MLH1 was only significantly associated with patients’ age.

16 specimens showed positive REV-7 expression, while 48 specimens were REV-7 negative.

Interestingly, 50% of patients with chemoresistant disease and 16,7% of patients with chemosensitive disease were REV-7 positive.

This difference was statistically significant.

Moreover, REV-7 positivity was significantly associated with chemoresistance, various clinicopathological parameters and patients’ prognosis and survival.

Conclusion Loss of MLH1 expression was only found to be significantly associated with lower patients’ age.

Positive immunohistochemical REV-7 expression was significantly associated with various clinicopathological parameters, while it was also associated with significantly lower survival and greater hazard.

REV-7 positive percentages were significantly higher in patients with chemoresistant disease.

Our findings imply that immunohistochemical staining for REV-7 could potentially be used as a predictive tissue marker for TGCT tumors.

Moreover, targeting of REV-7 protein, could represent a potential therapeutic strategy for chemoresistant TGCT cases.

The implementation of well-designed studies on a larger scale is of utmost importance, in order to draw safer conclusions.

Additional studies are needed so as to draw safer conclusions.